Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience (TWST) to $55 from $50 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $56 from $52 at Evercore ISI
- Twist Bioscience price target raised to $55 from $50 at Guggenheim
- Cathie Wood Pours $16M into Circle Stock, Dumps ROKU, TSM, TWST, BLSH
- Twist Bioscience Stock (TWST) Tumbles after Senior Executive Offloads $2M in Shares
- Cathie Wood Loads Up on Biotech Stocks While Trimming Several Tech Positions